Suppr超能文献

肾移植受者和候选者的肥胖问题。

Obesity in kidney transplant recipients and candidates.

机构信息

Department of Medicine, Division of Nephrology and Hypertension, Loyola University Medical Center, Maywood, IL 60153, USA.

出版信息

Am J Kidney Dis. 2010 Jul;56(1):143-56. doi: 10.1053/j.ajkd.2010.01.017. Epub 2010 May 10.

Abstract

The prevalence of obesity in dialysis patients is increasing, and as a result, more obese dialysis patients are being evaluated for kidney transplant. Despite several limitations associated with the use of body mass index (BMI), BMI is commonly used to define obesity, with many transplant centers using BMI of 30-35 kg/m(2) as a limit for transplant eligibility. This limit evolved from the belief that obese patients have more complications and shorter transplant and patient survival than ideal-weight patients. Data for obesity and posttransplant complications are conflicting, with the exception of increased risk of postoperative wound complications, and there are no large trials showing a benefit of weight loss before transplant on subsequent patient or transplant survival. In our opinion, patient death and transplant failure rates in patients with BMI of 30-35 kg/m(2) are low enough that these individuals should not be excluded from transplant. Weight gain posttransplant is relatively common, and although sustained weight loss through conservative intervention is difficult to achieve, prevention of weight gain is a more feasible goal that should be addressed routinely. Although obesity is a complex and often multifactorial clinical condition that includes nonmodifiable factors, obese individuals often are viewed as being solely responsible for their obesity. Accordingly, in addition to encouragement of lifestyle modification, available pharmacologic and surgical options should be reviewed in appropriate patients. After pharmacologic and/or surgical interventions, close monitoring of immunosuppressive medications is necessary because of variability in drug absorption.

摘要

透析患者肥胖的患病率正在增加,因此,越来越多的肥胖透析患者正在接受肾移植评估。尽管与体重指数 (BMI) 的使用相关存在几个局限性,但 BMI 通常用于定义肥胖,许多移植中心将 BMI 为 30-35 kg/m(2) 作为移植资格的限制。这个限制源于这样一种信念,即肥胖患者比理想体重患者有更多的并发症,移植和患者的生存率更短。肥胖和移植后并发症的数据存在矛盾,除了手术后伤口并发症的风险增加外,没有大型试验表明移植前减肥对随后的患者或移植生存率有获益。在我们看来,BMI 为 30-35 kg/m(2)的患者的死亡率和移植失败率足够低,不应将这些患者排除在移植之外。移植后体重增加相对常见,虽然通过保守干预实现持续减肥很困难,但预防体重增加是一个更可行的目标,应该定期解决。尽管肥胖是一种复杂且常常多因素的临床情况,包括不可改变的因素,但肥胖者通常被认为仅应对其肥胖负责。因此,除了鼓励生活方式改变外,还应在适当的患者中审查可用的药物和手术选择。在药物和/或手术干预后,由于药物吸收的变异性,需要密切监测免疫抑制药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验